Evidence map›Paper›PMID 40116719›Full record

ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Comparative Efficacy of Recombinant FVIII and Recombinant FVII Biosimilars in Severe Hemophilia A.

Meganathan Kannan, Chitrali Laha Roy, Prakasha Kempaiah, Ravi Ranjan, Manoranjan Mahapatra, Renu Saxena, Jawed Fareed

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Meganathan KannanBlood and Vascular Biology Research Lab, Department of Biotechnology, Central University of Tamil Nadu, Thiruvarur, India.ORCID 0000-0002-6107-4228
Chitrali Laha RoyBlood and Vascular Biology Research Lab, Department of Biotechnology, Central University of Tamil Nadu, Thiruvarur, India.
Prakasha KempaiahDepartment of Molecular Pharmacology and Neuroscience, Loyola University Chicago, Chicago, IL, USA.ORCID 0000-0002-2901-0339
Ravi RanjanDepartment of Hematology, All India Institute of Medical Sciences, New Delhi, India.
Manoranjan MahapatraDepartment of Hematology, All India Institute of Medical Sciences, New Delhi, India.
Renu SaxenaDepartment of Hematology, All India Institute of Medical Sciences, New Delhi, India.
Jawed FareedDepartment of Molecular Pharmacology and Neuroscience, Loyola University Chicago, Chicago, IL, USA.ORCID 0000-0003-3465-2499

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundHemophilia A (HA) occurs due to the deficiency of factor VIII (FVIII). Individuals with HA generally present with elevated activated partial thromboplastin time (aPTT) and normal prothrombin time (PT). The only possible treatment for this bleeding condition is factor concentrate.AimThe aim of this study is to compare the effect of recombinant factor VIII (rFVIII) and recombinant factor VII (rFVII) on prothrombin time (PT), activated partial thromboplastin time (aPTT), FVIII and FVII in severe HA.MethodologyA mixing study was conducted on 30 samples of severe HA patients to assess the correction of PT, aPTT, FVIII, and FVII values using biosimilars of rFVIII (NovoEight and Kogenate FS) and rFVII (NovoSeven and AryoSeven) using a fully automated coagulation analyser 'Ceveron alpha'.ResultsAll the four drugs demonstrated a significant alteration for both PT (

Indexed as

Biosimilar PharmaceuticalsFactor VIIaFactor VIIIHemophilia AAdolescentAdultFemaleHumansMaleMiddle AgedPartial Thromboplastin TimeProthrombin TimeRecombinant ProteinsBiosimilar PharmaceuticalsF8 protein, humanFactor VIIaFactor VIIIRecombinant Proteinsbleedingcoagulation parametersHemophilia Arecombinant FVIIrecombinant FVIII

Identifiers

PMID40116719
PMCPMC11930464

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.